Pfizer’s Q1FY23 performance beat our estimates on the profitability front drivenby strong control over costs. Revenues declined 20.9% YoY (+7.9% QoQ) to Rs 5.9bn (I-Sec: Rs 5.9bn) on a high covid-led base.